USD 1.19
(-8.1%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 65.62 Million USD | 86.42% |
2022 | 35.2 Million USD | 2.35% |
2021 | 34.39 Million USD | 113.15% |
2020 | 16.13 Million USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
1999 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 84.46 Million USD | 15.56% |
2024 Q1 | 73.09 Million USD | 11.39% |
2023 Q3 | 51.43 Million USD | 12.61% |
2023 FY | 65.62 Million USD | 86.42% |
2023 Q4 | 65.62 Million USD | 27.58% |
2023 Q2 | 45.67 Million USD | 16.07% |
2023 Q1 | 39.35 Million USD | 11.79% |
2022 Q3 | 29.54 Million USD | 1.07% |
2022 FY | 35.2 Million USD | 2.35% |
2022 Q4 | 35.2 Million USD | 19.14% |
2022 Q2 | 29.23 Million USD | -18.01% |
2022 Q1 | 35.65 Million USD | 3.66% |
2021 Q4 | 34.39 Million USD | 1.24% |
2021 FY | 34.39 Million USD | 113.15% |
2021 Q3 | 33.97 Million USD | 43.26% |
2021 Q2 | 23.71 Million USD | 18.39% |
2021 Q1 | 20.03 Million USD | 24.13% |
2020 Q1 | 1.84 Million USD | 0.0% |
2020 Q3 | 9.06 Million USD | 9.86% |
2020 FY | 16.13 Million USD | 0.0% |
2020 Q2 | 8.24 Million USD | 348.02% |
2020 Q4 | 16.13 Million USD | 78.08% |
2019 Q3 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2000 Q1 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q2 | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
1999 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | -445.767% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -244.008% |
Amicus Therapeutics, Inc. | 59.69 Million USD | -9.929% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -576.108% |
bluebird bio, Inc. | 22.91 Million USD | -186.326% |
Cara Therapeutics, Inc. | 2.82 Million USD | -2226.232% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 82.993% |
Myriad Genetics, Inc. | 20.1 Million USD | -226.483% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -71.339% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 15.225% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.211% |
Waters Corporation | 516.23 Million USD | 87.288% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.71% |
Biogen Inc. | 2.52 Billion USD | 97.404% |
Nektar Therapeutics | 16.1 Million USD | -307.571% |
Perrigo Company plc | 1.14 Billion USD | 94.248% |
Dynavax Technologies Corporation | 53.29 Million USD | -23.143% |
Illumina, Inc. | 587 Million USD | 88.821% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -532.694% |
Heron Therapeutics, Inc. | 42.11 Million USD | -55.837% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 94.073% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -496.681% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.457% |
FibroGen, Inc. | 41.56 Million USD | -57.88% |
Agilent Technologies, Inc. | 1.03 Billion USD | 93.635% |
OPKO Health, Inc. | 65.69 Million USD | 0.113% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 26.387% |
Exelixis, Inc. | 17.32 Million USD | -278.82% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 97.441% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -333.584% |
Abeona Therapeutics Inc. | -2.44 Million USD | 2785.065% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 91.118% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -130.864% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 79.674% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -748.939% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 48.572% |
Blueprint Medicines Corporation | 21.22 Million USD | -209.207% |
Insmed Incorporated | 83.24 Million USD | 21.172% |
TG Therapeutics, Inc. | 39.82 Million USD | -64.787% |
Incyte Corporation | 62.97 Million USD | -4.21% |
Emergent BioSolutions Inc. | 328.9 Million USD | 80.048% |